{"groups":[{"description":"Participants received blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"FG000","title":"Placebo+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Participants received blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"FG001","title":"Atezolizumab+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Eligible participants received open-label atezolizumab as monotherapy.","id":"FG002","title":"Atezolizumab Monotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"6"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Protocol Deviation"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Symptomatic Deterioration"},{"reasons":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"28"},{"groupId":"FG002","numSubjects":"24"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"303"},{"groupId":"FG001","numSubjects":"332"},{"groupId":"FG002","numSubjects":"272"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"47"},{"groupId":"FG001","numSubjects":"76"},{"groupId":"FG002","numSubjects":"60"}],"type":"Study Terminated By Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"400"},{"groupId":"FG001","numSubjects":"451"},{"groupId":"FG002","numSubjects":"362"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"400"},{"groupId":"FG001","numSubjects":"451"},{"groupId":"FG002","numSubjects":"362"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Stage 1 included atezolizumab+gemcitabine+carboplatin arm or placebo+gemcitabine+carboplatin arm. Participants ineligible for cisplatin-based chemo were enrolled in this stage. Stage 2 included addition of atezolizumab monotherapy arm and allowed participants who were eligible for cisplatin-based chemotherapy. Study is considered \"Completed\" because all pre-planned study analyses have been preformed for primary and secondary endpoints.","recruitmentDetails":"Participants were enrolled in 221 sites in 35 countries."}